Archon Biosciences Raises $20M to Develop AI-Optimized Antibody Cages for Disease Treatment

Archon Biosciences has emerged from stealth with $20 million in seed funding led by Madrona Ventures to develop Antibody Cages, computationally designed protein structures optimized with AI for treating cancer and other diseases. The technology builds on protein design research linked to a recent Nobel Prize awarded to University of Washington biochemist David Baker.

GGeorge Ueda DDavid Baker UUniversity of Washington